个人信息
Personal Information
联系方式
Contact Information
个人简介
Personal Profile
医学博士,主任医师,博士研究生导师,副教授,同济大学附属第十人民医院消化内科 国内知名IBD内科专家
美国内布拉斯加医学中心访问学者、美国芝加哥大学IBD中心交流学者。获同济大学首批全英文授课教师资格、上海市第十人民医院首批“研究型医师A类”称号及资助。
主持IBD领域国家自然科学基金项目4项(在研1项),牵头全国多中心临床研究1项(在研),牵头国内多中心III期临床研究1项(在研)、上海第十人民医院首届研究型医师A类资助(在研)。担任国家自然科学基金评审专家,《中华炎性肠病杂志》及Stem Cell Research & Therapy, JDD,Gastroenterology Report等中外期刊审稿专家。在Clinical and translational medicine, InflammBowel Dis, Stem Cell Research &Therapy, Inflammation research,J Inflamm Res等发表中英文论文近50余篇。
指导研究生情况:
① 指导研究生舒伟刚参加2024 the 11th Annual meeting of Asican Organization for Crohn’s and Colitis (亚洲克罗恩病与结肠炎年会, AOCC 2024, 中国西安)”, June 12-14, 2024, Oral presentation
② 指导研究生舒伟刚参加2024 the 19th Congress of European Crohn’s and Colitis Organisation (ECCO) (Stockholm, Sweden), February 21-24, 2024, “Basic science, Poster P05”;
③ 指导研究生舒伟刚参加 2022 the 10th Annual meeting of Asican Organization for Crohn’s and Colitis (亚洲克罗恩病与结肠炎年会, AOCC 2022, 韩国首尔)”,“Best oral awards (最佳口头汇报奖)”;
④ 指导研究生张蕾参加 2021 the 9th Annual meeting of Asican Organization for Crohn’s and Colitis (亚洲克罗恩病与结肠炎年会, AOCC 2021, 中国广州),“Distinguished investigator awards (杰出研究者奖)”。
⑤ 指导研究生汪海潮参加 2021 the 9th Annual meeting of Asican Organization for Crohn’s and Colitis (亚洲克罗恩病与结肠炎年会, AOCC 2021, 中国广州),E- Poster。
⑥ 指导研究生吴亚玲参加 2021 the 9th Annual meeting of Asican Organization for Crohn’s and Colitis (亚洲克罗恩病与结肠炎年会, AOCC 2021, 中国广州),E-Poster。
发表的主要论文:
(1) Weigang Shu, Yongheng Wang, Zhuoma Deji, Chuanding Li, Chunqiu Chen,Wenjun Ding, Peng Du, Xiaolei Wang. Infliximab Modifies CD74-Mediated Lymphatic Abnormalities and Adipose Tissue Alterations in Creeping Fat of Crohn’s Disease. inflammation research. Inflamm Res. 2024 May 7.
(2) Wang H, Yan G, Wu Y, Zhuoma D, Liu Z, Gao X, Wang X. Fecal microbiota related to postoperative endoscopic recurrence in patients with Crohn's disease. Gastroenterol Rep (Oxf). 2024 Mar 23;12:goae017. doi: 10.1093/gastro/ goae017. eCollection 2024. Q2 IF 3.60
(3) Li S, Zheng Y, Yang Y, Yang H, Han C, Du P, Wang X, Yang H. Diagnosis and classification of intestinal diseases with urine by surface-enhanced Raman spectroscopy. Spectrochim Acta A Mol Biomol Spectrosc. 2024 Feb 23; 312: 124081.
(4) Lei Zhang, Chen Ye2, Peng Li , Chuanding Li , Weigang Shu , Yujie Zhao and Xiaolei Wang. ADSCs stimulated by VEGF-C alleviate intestinal inflammation via dual mechanisms of enhancing lymphatic drainage by a VEGF-C/ VEGFR-3-dependent mechanism and inhibiting the NF-κB pathway by the secretome. Stem Cell Research & Therapy, (2022) 13:448.
(5) Yaling Wu, Zijie Wang, Mengmeng Xing, Bingyan Li, Zhiyuan Liu, Peng Du, Huinan Yang, Xiaolei Wang. The Specific Changes of Urine Raman Spectra Can Serve as Novel Diagnostic Tools for Disease Characteristics in Patients with Crohn's Disease. J Inflamm Res. 2022 Feb 9;15:897-910. doi: 10.2147/JIR.S341871.
(6) Haichao Wang, Yaling Wu, Chen Ye, Zhanju Liu, Xiaolei Wang. Perianal disease onset age is associated with distinct disease features and need for intestinal resection in perianal Crohn’s disease:a ten-year hospital-based observational study in China. BMC Gastroenterol. 2021; 21: 376. Published online 2021 Oct 14. doi: 10.1186/ s12876-021-01961-9.PMCID: PMC8515669.
(7) Bingyan Li,Yaling Wu,Zijie Wang,Mengmeng Xing,Weimin Xu,Yilian Zhu, Peng Du, Xiaolei Wang, Huinan Yang. Non-invasive diagnosis of Crohn's disease based on SERS combined with PCA-SVM. Anal Methods. 2021 Nov 18;13(44):5264-5273.
(8) Yaling Wu, Lei Zhang, Jingli Cao, Haichao Wang, Chen Ye, Deji Zhuoma, Pengyu Yang, Xiaolei Wang. Efficacy of infliximab treatment on the mucosal healing of different intestinal segments in patients with ileocolonic Crohn’s disease. Therap Adv Gastroenterol. 2020 Dec 21;13:1756284820976923. PMID: 33425009. DOI:10.1177/1756284820976923
(9) Haichao Wang , Chen Ye , Yaling Wu Pengyu Yang , Chunqiu Chen, Zhanju Liu, Xiaolei Wang. Exosomes in Inflammatory Bowel Disease: What Have we learned so far? Curr Drug Targets. 2020 Apr;21(14):1448-1455.doi: 10.2174 /13894 501216662004281023 30.
(10) Xiaolei Wang, Jingli Cao, Haichao Wang, Chen Ye. Risk Factors Associated with Infusion Reactions to Infliximab in Chinese Patients with Inflammatory Bowel Disease: A Large Single-Center Study. Med Sci Monit, 2019 Mar; 25: 2257-2264 eISSN: 1643-3750 PMID: 30917108
(1) 国家自然科学基金面上项目,82470535 ,FABP5调控肠系膜淋巴管内皮细胞脂肪酸氧化促进淋巴管功能减轻克罗恩病肠道炎症的机制研究,2025/01-2028/12,49万,在研,主持
(2) 2023年上海市第十人民医院研究型医师A类资助;10万,主持,在研
(3) 2022 爱在延长基金会青蜂科研资助项目《乌司奴单抗联合肠内营养治疗中-重度活动期克罗恩病伴小肠狭窄的疗效与安全性评估:一项多中心、前瞻性、开放标签的随机对照研究》,(注册号ChiCTR2300075237;国家医学研究登记备案号:MR-31-23-028689;伦理号:SHSY-IEC-5.0/ 23K7/ P02),25万,主持,2013/01-2015/12,在研
(4) 国家自然科学基金面上项目,81970449,肠系膜脂肪干细胞分泌的外泌体miR-132-3p靶向RASA1调节淋巴管内皮功能对实验性肠系膜炎和肠炎的作用机制研究,2020/01-2023/12,55万,主持,结题
(5) 国家自然科学基金面上项目, 81670476,脂肪干细胞对实验性肠炎肠道淋巴管生成的影响及其对免疫调节机制的研究,2017/01-2020/12,58万,主持,结题
(6) 国家自然科学基金青年项目,81200260,VEGFR-3介导的淋巴管生成在实验性炎症性肠病发病中的作用和对慢性炎症的调控研究,2013/01-2015/12,23万,主持,结题
共获得国家自然科学基金资助项目4项,目前在研项目如下:
在研项目:
(1) 国家自然科学基金面上项目,82470535,FABP5调控肠系膜淋巴管内皮细胞脂肪酸氧化促进淋巴管功能减轻克罗恩病肠道炎症的机制研究,2025/01-2028/12,49万,在研,主持。
(2) 同济大学“医学+X”交叉研究项目,基于人工智能驱动的小肠克罗恩病的精准分型与预后预测体系的建立与应用, 2025.1-2027.12,20万
(3) 浙江爱在延长炎症性肠病基金会“青峰科研资助项目”乌司奴单抗联合肠内营养治疗中-重度活动期克罗恩病伴小肠狭窄的疗效与安全性评估.ChiCTR2300075237),2023.1-2025.12,第一负责人,经费25万。
(4) 上海市第十人民医院首届研究型医师A类资助项目(在研),经费10万。
1.指导研究生汪海潮参加 2021the 9th Annual meeting of AsicanOrganization for Crohn’s and Colitis (亚洲克罗恩病与结肠炎年会,AOCC 2021, 中国广州),E-Poster。
2. 指导研究生吴亚玲参加 2021the 9th Annual meeting of AsicanOrganization for Crohn’s and Colitis (亚洲克罗恩病与结肠炎年会,AOCC 2021, 中国广州),E-Poster。
3. 指导研究生张蕾参加 2021the 9th Annual meeting of AsicanOrganization for Crohn’s and Colitis (亚洲克罗恩病与结肠炎年会, AOCC2021, 中国广州),“Distinguishedinvestigator awards(优秀研究者奖)”。
4. 指导研究生舒伟刚参加 2022the 10th Annual meeting of AsicanOrganization for Crohn’s and Colitis (亚洲克罗恩病与结肠炎年会, AOCC2022, 韩国首尔)”,“Best oral awards (最佳口头汇报奖)”。
5. 指导研究生李传顶的研究获2023 年论文投稿《基于贝叶斯网络预测小肠狭窄型克罗恩病患者发生手术风险的工具开发与验证》获中华医学会第二十三次全国消化系病学术会议“论文发言”交流 (2023 CGC,中国武汉)
文件上传中...